Clinical Trial Update: Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of CHF 1535 200/6µg in not adequately controlled asthma has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF 1535 200/6µg

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2026-03-19